XPERTT: QVM149 vs Dual Therapy in Asthma

Phase 3, randomised, open-label trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in asthma (2 arms), sponsored by Parraga Lab. Primary endpoints: Change from baseline airway function measured using 129-Xenon MRI ventilation defect percent at Day 14 and Difference in change from baseline airway function measured using 129-Xenon MRI ventilation defect percent at Day 14. Planned start Dec 2021; status: withdrawn.